d gaser
21 Sep 2017
Re: Wellstat littigation costs BTG 55m Hi protherics did you read the document I posted ,regarding the future problems that might hurt certain products this year, if not I have re posted it below .There you will see, it's not just the wellstat litigation that could hurt the bottom line, but there are several others ,one such product that could hit our bottom line , as you know there are currently no competitive products to CroFab®, how ever it appears the Instituto Bioclona Mexican company may launch a competitor product to CroFab® around its copy of our ant venom product, it’s expected to be launched in Oct this year, see chapter 1V competition on the link below . www.iii.co.uk/research/LSE:BTG/news/item/2405018/annual-financial-report?context=LSE:BTGpersonally don't see anybody coming in at the moment to take BTG out ,but I wouldn't be surprised to see BTG take somebody else over, or merge with another company, however, that company must be making a profit, and be in a strong position to expand, as that is the only way BTG can fill the loss of the wellstat product, plus any losses from any new competition. However BTG could make an offer to buy out the wellstat product, instead of licensing it, that way, BTG would increase their worldwide market ,rather than just serving the US market and they wouldn't have to pay the $55 m fine plus costs.What ever they do this has all ready been priced in as this news has been around for several months now and its now behind us .now lets hope BTG can find a magic money tree from some where which allows BTG to continue growing .I just hope we don't see any more free shares for the BOD now ,as they have obviously fowled up once again ,BE HAPPYDAVE
up protherics
20 Sep 2017
Re: Wellstat littigation costs BTG 55m Dave GThanks for the linksPersonally I am not surprised by todays ruling.. I would imagine that the same people who advised BTG over Biocompatables have been involved with Wellstat somewhere in the chain.In terms of future skellitons in the cupboard my guess is that we are going to have a black hole next year.Lemtrada royalties endingAbiraterone royalties decliningAs you are aware I am completely fed up with this company and their ineptness of late..For me I am hoping for a takeover at £8.00 in the short term.. I.E over next six months.. Either way I will not be holding come the spring
d gaser
20 Sep 2017
Wellstat littigation costs BTG 55m Well that's another $55m taken from this years accounts, last year BTG was ordered to pay $36m after BTG's acquisition of Biocompatible , I wonder if there is any more litigation against BTG out there other than the one against GSK .In the notice I posted the other day this problem was noted it stated BTG is in a current dispute with Wellstat over the commercialisation of Vistogard®. Wellstat are seeking damages and to terminate the commercialisation agreement under which BTG obtained rights to sell Vistogard in the US. A trial has been heard in the Court of Chancery of the State of Delaware but no judgement has yet been issued. IT HAS NOW It seems clear to me that the market were aware of this litigation ,and have priced in this fine ,lets just hope we don't lose the product as well, as any sales from this product would hopefully cover the fine ,but I must admit I'm not hopeful.Bad day for BTG BE HAPPYDAVE
Denis Filby
20 Sep 2017
Re: Damn Yanks Not quite sure what it is about. Seems like a technicality. See the original agreement dated 2011[link]
rikid
20 Sep 2017
Damn Yanks 55.8 million . Another British company shafted by the US establishment.
d gaser
18 Sep 2017
Re: Stocking of Antidotes in U/S Hospita... Hi Protherics there is some interesting data regarding problems that might arise over the next year on BTG web site ,I have lifted the web link see below Crofab is one possibility see BTG info .see link below and look for change 2016/17 crow fab www.iii.co.uk/research/LSE:BTG/news/item/2405018/annual-financial-report?context=LSE:BTGI’m also putting up a link to varicose veins report for Europe, now I have no idea why BTG has still not submitted Varithena for European approval yet,which seems a bit odd . Europe’s population in the 27 countries of Europe is about the same as the USA and Canada ,and if only 5 % of that population have varicose veins ,and only 2% use Varithena® it still equates to a bigger market than we presently have in the USA ,when it comes to the use of BTG Varithena® . The same could also be said for the Australian /Asia market, so why are BTG not looking at these markets? maybe it’s because they have now determined Varithena® is not going to produce the mega sales it first thought and have now decided to look elsewhere ,but if, that is the case, then why are they not licencing out Varithena to another company to serve these areas ? see link to market value for Europe belowwww.medgadget.com/2017/09/europe-varicose-vein-treatment-market-worth-usd-114-37-million-by-2021-market-data-forecast.html Another interesting view regarding our growth potential is available here at forbes, see link www.forbes.com/companies/btg/ As for taking over another company well that is all ways a possibility, but it would have to be a company that already has a good profit making portfolio, if things do go pair shaped here .BE HAPPYDAVE
up protherics
15 Sep 2017
Re: Stocking of Antidotes in U/S Hospita... Stout hThey have hedged the exchange rate. I'm my view.its down to their usual innept ness of la
stout-hart
15 Sep 2017
Re: Stocking of Antidotes in U/S Hospita... Up p"Its a pitty btg pr team hadn't done a better job.. Look at the price today."Surely a response to a weaker $ and therefore lower US earnings in sterling terms.
up protherics
15 Sep 2017
Re: Stocking of Antidotes in U/S Hospitals DaveIts a pitty btg pr team hadn't done a better job.. Look at the price today.Whats your guess on this.. I am anticipating some director sales along with a negative outcome re wellstat.. Also royalties falling from Lemtrada and the prostate cancer treatment.Hopefully someone may be looking at bidding for this.I am also a holder of quantum pharma which is currently in a takeover situation with Clinigen.. should BTG be looking at acquisitions like quantum Pharma..?????
d gaser
15 Sep 2017
Stocking of Antidotes in U/S Hospitals At long last we have received some good news, it appears the US have included two of our drugs to there Stocking of Antidotes in Hospitals that Provide Emergency Care' now That should help sales move north in the US BE HAPPYDAVE . published online by the Annals of Emergency Medicine (AEM). PHILADELPHIA, September 13, 2017 /PRNewswire/ -- BTG plc (LSE: BTG), the global specialist healthcare company, announces the inclusion of two of its oncology-related antidote products in the revised 'Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care' published online by the Annals of Emergency Medicine (AEM). The previous version of the stocking guidelines was published in 2009, prior to the approval and availability of Voraxaze ® (glucarpidase) and Vistogard ® (uridine triacetate), which are used to reverse toxicities that can occur from particular chemotherapy treatments. These two BTG products have now been added to the guidance. The recommendations have been updated by a multidisciplinary expert healthcare panel that have experience with the medical and logistical nature of using emergency care products to promptly treat patients exposed to a number of poisons. In total, 45 antidotes were considered and 44 were recommended for stocking, including the timeframe in which the products should be available to administer to patients.Full article www.thestreet.com/story/14303399/1/vistogard-and-voraxaze-added-to-revised-guidelines-for-stocking-of-antidotes-in-us-hospitals.htmlBE HAPPYDav
d gaser
24 Aug 2017
BTG grants to (SIO) It appears BTG have given the The Society of Interventional Oncology (SIO) a grant to nurture and support interventional oncology worldwide, BTG plc announce recently their 2017 Interventional Oncology / Immuno-Oncology research grant recipients. The investigators and project proposals that have been awarded grants are www.prnewswire.co.uk/news-releases/sio-announces-first-grants-in-interventional-oncology--immuno-oncology-research-programme-626969861.htmlRafael Duran, MDCentre Hospitalier Universitaire Vaudois Investigating the Immunobiology of Hepatocellular Carcinoma in Patients Undergoing Y90 RadioembolizationJoseph P. Erinjeri, MD, PhDMemorial Sloan Kettering Cancer Center T-Cell Clonality and Cancer Neoantigen Presentation Following Interventional Oncology (IO) Therapies: Which IO Techniques Optimally Stimulate the Immune System?Florian J. Fintelmann, MDMassachusetts General Hospital A Pilot Study of Cryoablation Combined with Immune Checkpoint Inhibitor Therapy in Patients with PD-1 Refractory Metastatic Melanoma: Prospective Clinical Research and Correlative Laboratory StudiesStephen Hunt, MD, PhDUniversity of Pennsylvania TAEVax: Immunobiologic Treatment Effects of Embolization in a Rat HCC Model"We are very pleased that through the generosity of BTG, SIO has been able to fund the most meritorious, cutting-edge research that combines the strengths of interventional oncology and immuno-oncology-two disciplines that hold great promise for improving cancer therapy. The large number of high quality submissions to this grant call attests to the intense interest of interventional oncologists worldwide.for more info go to www.prnewswire.co.uk/news-releases/sio-announces-first-grants-in-interventional-oncology--immuno-oncology-research-programme-626969861.html BE HAPPYDav
dave297
21 Aug 2017
Shire Would their need for a credible FD tempt them to acquire BTG to take on Luise & Ralph or would they they just try to poach Ralph anyway ?
d gaser
14 Aug 2017
Telegraph article Iain Withers article in the telegraph see link for full article 12 August 2017 • 7:10pm FTSE 250-listed drug company BTG is to plough new investment into cutting-edge cancer therapies in a bid to shake up the fast growing global immuno-oncology (IO) drugs market.BTG’s play in IO – a market worth $8bn (£6.2bn) a year today and projected to reach $50bn – is to develop medical devices that can deliver the immune system-boosting drugs directly to the cancer-affected part of the body using specially-designed needles, catheters or probes.The British firm hopes this approach will prove more effective than the current method of ingesting the drug and altering the whole body’s immune system, which can lead to side effects, such as an attack on healthy cells rather than just tumour. www.telegraph.co.uk/business/2017/08/12/drugmaker-btg-bets-devices-help-treat-cancer/BE HAPPYDAv
d gaser
09 Aug 2017
Re: Cor Numis is has just released an up date but to be honest I don't think we will see 900 any time soon ,it's more than likely to head back below £6 ,unless we get some good news soon BE HAPPYDAVE Reporting a potential upside of 0.39%, Numis hold steady the price target of BTG PLC (LON:BTG) at 900.00GBX On 07/13/2017, Numis released a statement about BTG PLC (LON:BTG) maintained the target price at 900.00GBX that suggested an upside of 0.34%.Having a price of 649.50GBX, BTG PLC (LON:BTG) traded -1.15% lower on the day. With the last stock price up 2.62% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.06% over the same period. BTG has recorded a 50-day average of 674.66GBX and a two hundred day average of 629.49GBX. Trade Volume was down over the average, with 87,164 shares of BTG changing hands under the typical 705,137 BTG PLC has PE ratio of 75.12 with a one year low of 528.36GBX and a one year high of 738.50GBX and has a market capitalization of 0 GBX.
up protherics
02 Aug 2017
Re: Cor pauloverdi I don't know about the others, but I am still here..INMO...Nothing much will happen for at least six months.. If anything only negative news will transpire, albeit in a small way ( hopefully )As you probably already know I have held this for a long time..All I can say is that I will be selling after the next surge and not holding for a possible takeover.. However if they started paying some sort of dividend then I would re consider.As Roger Moore once said.. The shows not over until fat lady sing
